BioSpace News Archive

Veru Inc. (NASDAQ: VERU) today announced results from a preclinical study of sabizabulin demonstrating robust anti-inflammatory activity with improved outcomes in an Influenza-Induced Pulmonary Inflammation Mouse Acute Respiratory Distress Syndrome (ARDS) Model.

Nobelpharma America, specialists in developing treatments and medical devices for rare diseases, announced it has received certification by Great Places to Work® for its values-based company culture and the quality of the workplace environment.

Edesa Biotech, Inc. announced the World Health Organization has adopted the international nonproprietary name “paridiprubart” for the company’s monoclonal antibody candidate, EB05.

Vallon Pharmaceuticals, Inc., urges its stockholders of record as of March 6, 2023 to vote in favor of all of the proposals outlined in the Company’s definitive Proxy Statement for the upcoming Special Stockholder Meeting to be held virtually at 9:00 AM ET on April 12, 2023.

AnaBios Corporation today announced the acquisition of Cell Systems, a human primary cell and cell culture media company located in Kirkland, Washington.

The Cystic Fibrosis Foundation recently agreed to provide up to $15.5 million to Anagram Therapeutics (formerly known as Synspira Therapeutics) to conduct early-stage clinical trials of a novel enzyme replacement therapy.

Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) announced today that it has received 510(k) clearance for BIASURGE™ Advanced Surgical Solution (“BIASURGE™").

SOPHiA DDMTM HRD Solution will help empower clinical researchers to advance cancer research SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Tel Aviv Sourasky Medical Center, the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities.

Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells to address multiple disease indications, announces that the U.S. Food and Drug Administration (FDA) has authorized the expansion of its pivotal Phase 3 EXTINGUISH ARDS trial to evaluate the safety and efficacy of ExoFlo™.

The Maryland Stem Cell Research Commission announces the appointment of Ruchika Nijhara, Ph.D., MBA, as executive director of the Maryland Stem Cell Research Fund.